Such myeloid sarcomas have been reported in MA9Ras xenografts expressing KMT2A-MLLT3 fusion protein, limiting the survival efficacy of the IL1RAP antibody, which otherwise showed strong anti-leukemic effect in the bone marrow [31]. Here, IL1RAP is linked to myeloid sarcoma.